title: Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery.
abstract: Inhibition of the cyclooxygenase (COX)-2 enzyme has been shown previously to reduce pain and inflammation. Valdecoxib is a new highly selective COX-2 inhibitor with a rapid onset of action and significant analgesic properties. This study compared the analgesic efficacy of valdecoxib and rofecoxib in treating postoperative pain in patients undergoing oral surgery. This randomized, double-blind, placebo-controlled study compared the efficacy of 40 mg valdecoxib with that of 50 mg rofecoxib and placebo. Efficacy was assessed by the onset of analgesia, pain intensity levels, and pain relief over 24 hours, time-weighted sum of total pain, sum of pain intensity difference, the percentage of patients requiring rescue medication and experiencing regimen failure, and patients' global evaluation. Patients receiving valdecoxib experienced a significantly quicker onset of analgesia, significantly improved pain relief, and lower pain intensity compared with patients receiving rofecoxib and greater satisfaction with their study medication after a single dose. Valdecoxib also demonstrated efficacy that was superior to that of rofecoxib with respect to the percentage of patients requiring rescue medication or experiencing regimen failure (p < or =.05). Valdecoxib, rofecoxib, and placebo were equally well tolerated. This study demonstrates that valdecoxib provides significantly greater analgesic efficacy than rofecoxib in the management of pain after oral surgery.
authors.affiliation: PPD Development, Dental Center, Austin, Texas, USA.
authors.forename: James
authors.initials: J
authors.lastname: Fricke
authors.forename: John
authors.initials: J
authors.lastname: Varkalis
authors.forename: Sam
authors.initials: S
authors.lastname: Zwillich
authors.forename: Rebecca
authors.initials: R
authors.lastname: Adler
authors.forename: Eliot
authors.initials: E
authors.lastname: Forester
authors.forename: David P
authors.initials: DP
authors.lastname: Recker
authors.forename: Kenneth M
authors.initials: KM
authors.lastname: Verburg
mesh_terms: D000293:Adolescent; D000328:Adult; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D007783:Lactones / Q000627:therapeutic use*; D008297:Male; D019647:Oral Surgical Procedures; D010147:Pain Measurement; D010149:Postoperative Pain / Q000517:prevention & control*; D012720:Severity of Illness Index; D013449:Sulfonamides / Q000627:therapeutic use*; D013450:Sulfones; D016896:Treatment Outcome; D000096926:Benzenesulfonamides
chemical_list: D016861:Cyclooxygenase Inhibitors; D007555:Isoxazoles; D007783:Lactones; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; C406224:valdecoxib; D000096926:Benzenesulfonamides